Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Investor Presentation (June 2020)
24 slides from Medipharm Labs's investor presentation, June 2020
Slide 1: A Global Platform Powering a Global Market
Lab: A Global Platform Powering a Global Market June 2020
Slide 2: Disclaimer
Disclaimer June 2020– This presentation was prepared by management of MediPharm Labs Corp. (“MediPharm Labs”). The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be
Slide 3: A global leader in manufacturing pure, trusted and precisely dosable cannabis concentrates
A global leader in manufacturing pure, trusted and precisely dosable cannabis concentrates for advanced derivative products. Serving the global medical and wellness markets. www.medipharmlabs.com | 3
Slide 4: MediPharm Labs – A Differentiated Global Growth Opportunity
MediPharm Labs – A Differentiated Global Growth Opportunity (1) Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of the Company’s operating inc
Slide 5: Key Milestones – First Licensed Extraction-Only Company in Canada
Key Milestones – First Licensed Extraction-Only Company in Canada www.medipharmlabs.com | 5
Slide 6: Flexible Business Model: Wholesale and White Label Platform
Flexible Business Model: Wholesale and White Label Platform www.medipharmlabs.com | 6
Slide 7: GMP Extraction Technology Platform to Drive Future Growth
GMP Extraction Technology Platform to Drive Future Growth Note: Launching of additional product lines remain subject to various risks and uncertainties, including the completion of applicable R&D, successful development of operations and regulatory approvals. See “Disclaimer – Cautionary Note Regard
Slide 8: Achieving GMP Certification to Access Emerging Global Markets
Achieving GMP Certification to Access Emerging Global www.medipharmlabs.com | 8
Slide 9: Global Operating Footprint - International Expansion Opportunities
Global Operating Footprint - International Expansion Opportunities www.medipharmlabs.com | 9
Slide 10: Multiple Strategic Private and White Label Supply Agreements
Multiple Strategic Private and White Label Supply Agreements www.medipharmlabs.com | 10
Slide 11: NEW PRODUCT
NEW PRODUCT MediPharm Labs CBD. REGULAR om? nu z The first in a new medicinal & wellness product line, MediPharm Labs CBD REGULAR FORMULA 25 is a pharma-quality CBD dominant oil. More to follow.... Zz. . Available Now at_ Medical cannabis. by SHOPPERS Ws MediPharm Labs Global Leader in Pharma-Qualit
Slide 12: Summary and Upcoming Catalysts
Summary and Upcoming Catalysts (1) All upcoming catalysts constitute forward-looking information and are subject to various risks and uncertainties. See “Disclaimer – Cautionary Note Regarding Forward-Looking Statements“. www.medipharmlabs.com | 12
Slide 13: Capital Structure and Ownership
Capital Structure and Ownership Stock Performance TSX:LABS – Up listed July 2019 (TSXV trading Oct 4, 2018) Capital Structure (as at December 31, 2019) $8.00 Volume (Millions) Price (C$ per Share) 8.0 Number Security (millions) $6.00 MediPharm Labs’ share price has 6.0 decreased by 18% Common Shares
Slide 14: Appendix
Appendix @medipharmlabs @medipharmlabs @medipharmlabs /medipharm-labs
Slide 15: 2019 Operational Highlights & Accomplishments
2019 Operational Highlights & Accomplishments • First full year of profitability and a top five cannabis revenue company in the Canadian cannabis industry • Signed multiple new supplier agreements with other Cannabis Act licensed holders, direct-to-consumer brands, provincial and private retailers i
Slide 16: 2019 Full Year Financial Summary
2019 Full Year Financial Summary Year Ended 3 Months Ended A ($000s) • Revenue $32.4M, a 25% decrease vs. $43.4M in Dec 31, 2019 Dec 31, 2019 Sept 30, 2019 June 30, 2019 Mar 31, 2019 Q3/19 Revenue $129,252 $32,444 $43,386 $31,472 $21,950 • Reflects reduction in average selling price A of bulk extrac
Slide 17: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Pat McCutcheon Keith Strachan Bobby Kwon Chief Executive Officer President, Co-Founder Chief Financial Officer 15-year career in pharmaceutical sales and marketing A healthcare business development expert, 25-year career in international consumer-pack
Slide 18: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Dr. Chris Talpas Nigel Dewbury Michael Perron Vice President, Quality & Scientific Affairs Head of Quality Vice President, Business Development A Chromatography expert with 24-years in the Pharmaceutical & Medical Device industry A CPA with a MAcc, Mi
Slide 19: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Warren Everitt Dr. Jake Golding Adam Miller Chief Executive Officer, Asia Pacific Head of Quality, Australia Head of Strategic Accounts, Australia Warren brings senior leadership in Asia Pacific 20-years in bio-tech, with expertise in chemistry, 8-yea
Slide 20: Research and Development
Research and Development Health Canada Cannabis Research Licence Cannabis Research Licence under Health Canada’s Cannabis Act and Cannabis Regulations. This licence permits MediPharm Labs to conduct controlled human administration trials of dried cannabis, cannabis extracts and concentrates, distill
Slide 21: Science Advisory Committee (SAC)
Science Advisory Committee (SAC) The SAC will collaborate with the MediPharm Labs management team on advancements in the emerging fields of cannabinoid extraction and cannabinoid-based derivative science. This work will serve to further enhance the Company’s manufacturing platform and research pract
Slide 22: Fiscal 2019 Financial Summary
Fiscal 2019 Financial Summary(1) Revenue Gross Profit Adjusted EBITDA(1) (Loss) Net Income (Loss) Before • $129.3M in FY/19, a 1,168% increase • $42.9 M in FY/19, a 973% increase vs. • $24.7M in FY/19, a 2,844% increase vs. vs. $10.2M in 2018 $4M in 2018 ($0.9M) in 2018 Tax • Reflects scaling of sal
Slide 23: Quarterly Financial Summary
Quarterly Financial Summary Revenue Gross Profit Adjusted EBITDA (1) Net Income (Loss) Before • $32.4M in Q4/19, a 25% decrease vs. • $10M in Q4/19, a 32% decrease vs. • $2.7M in Q4/19, a 72% decrease vs. $43.4M in Q3/19 $14.8M in Q3/19 $10.1M in Q3/19 Tax • ($2.4M) in Q4/19, a 144% decrease vs • Re
Slide 24: Please Contact for Additional Information
Please Contact for Additional Information Pat McCutcheon Chief Executive Officer @medipharmlabs Laura Lepore Vice President, Investor Relations @medipharmlabs and Communications @medipharmlabs Email: investors@medipharmlabs.com Phone: +1 416 913 7425 ext. 1525 /medipharm-labs